What Is the Acadia Pharmaceuticals Inc. (ACAD) Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. (“Acadia ” or “the Company”) (NASDAQ: ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation.
Investigation Details:
The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in corporate wrongdoing.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Acadia shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
How Did Acadia Pharmaceuticals Inc. (ACAD) Stock React to the Disclosures?
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”